Bosarge Patrick L, Raff Lauren Allen, McGwin Gerald, Carroll Shannon L, Bellot Scott C, Diaz-Guzman Enrique, Kerby Jeffrey D
From the Division of Acute Care Surgery, University of Alabama at Birmingham, Birmingham, Alabama.
J Trauma Acute Care Surg. 2016 Aug;81(2):236-43. doi: 10.1097/TA.0000000000001068.
The use of extracorporeal membrane oxygenation (ECMO) in the trauma population has been reported to have a mortality benefit in patients with severe refractory hypoxic respiratory failure. This study compares the early initiation of ECMO for the management of severe adult respiratory distress syndrome (ARDS) versus a historical control immediately preceding the use of ECMO for trauma patients.
A retrospective study was conducted at a single verified Level I trauma center. The study population was limited to trauma patients diagnosed with severe ARDS using the Berlin definition (PaO2/FIO2 ratio < 100). Patients managed with ECMO versus conventional ventilation (CONV) were compared. The primary outcome of interest was mortality; secondary outcomes included hospital length of stay, intensive care unit-free days, and ventilator-free days.
Fifteen ECMO patients managed from March 2013 to November 2014 were identified, as were 14 CONV patients managed from March 2012 to February 2013 who met the Berlin definition of severe ARDS. Data related to age, Injury Severity Scores (ISSs), admission lactic acid levels, base deficit, the number of transfused red blood cell units within the first 24 hours, and presence of severe traumatic brain injury were collected and were not statistically different between the groups. Likewise, Murray Lung Injury (MLI), Sequential Organ Failure Assessment (SOFA), and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores determined at the onset of severe ARDS were not statistically different between the groups. Median hospital stay (CONV, 28.0 days [14.0-47.0]; ECMO, 43.5 days [30.0-93.0]; p = 0.15), intensive care unit-free days (CONV, 0.0 days [0.0-5.0]; ECMO, 5.0 days [0.0-7.0]; p = 0.26), and ventilator-free days (CONV, 0.0 days [0.0-10.0]; ECMO, 8.0 days [0.0-19.0]; p = 0.13) were not statistically different between the groups. Mortality in the ECMO group was significantly reduced compared with the CONV group (ECMO, 13.3%; CONV, 64%; p = 0.01). Timing from the onset of severe ARDS to ECMO intervention occurred at a mean 1.9 ± 1.4 days.
Patients who were treated with ECMO for severe ARDS had an improved mortality compared with historical controls. ECMO should be considered at the early onset of severe ARDS to improve survival.
Therapeutic study, level IV.
据报道,在创伤患者中使用体外膜肺氧合(ECMO)对严重难治性低氧性呼吸衰竭患者有降低死亡率的益处。本研究比较了早期启动ECMO治疗成人严重急性呼吸窘迫综合征(ARDS)与创伤患者在开始使用ECMO之前的历史对照情况。
在一家经证实的一级创伤中心进行了一项回顾性研究。研究人群仅限于根据柏林定义(动脉血氧分压/吸入氧分数值<100)诊断为严重ARDS的创伤患者。比较了接受ECMO治疗与接受传统通气(CONV)治疗的患者。感兴趣的主要结局是死亡率;次要结局包括住院时间、无重症监护病房天数和无呼吸机天数。
确定了2013年3月至2014年11月接受ECMO治疗的15例患者,以及2012年3月至2013年2月符合严重ARDS柏林定义的14例接受CONV治疗的患者。收集了与年龄、损伤严重度评分(ISS)、入院时乳酸水平、碱缺失、最初24小时内输注红细胞单位数量以及严重创伤性脑损伤的存在情况相关的数据,两组之间这些数据无统计学差异。同样,在严重ARDS发作时确定的默里肺损伤(MLI)、序贯器官衰竭评估(SOFA)和急性生理与慢性健康状况评估II(APACHE II)评分在两组之间也无统计学差异。中位住院时间(CONV组,28.0天[14.0 - 47.0];ECMO组,43.5天[30.0 - 93.0];p = 0.15)、无重症监护病房天数(CONV组,0.0天[0.0 - 5.0];ECMO组,5.0天[0.0 - 7.0];p = 0.26)和无呼吸机天数(CONV组,0.0天[0.0 - 10.0];ECMO组,8.0天[0.0 - 19.0];p = 0.13)在两组之间无统计学差异。与CONV组相比,ECMO组的死亡率显著降低(ECMO组,13.3%;CONV组,64%;p = 0.01)。从严重ARDS发作到ECMO干预的时间平均为1.9±1.4天。
与历史对照相比,接受ECMO治疗严重ARDS的患者死亡率有所改善。在严重ARDS早期应考虑使用ECMO以提高生存率。
治疗性研究,IV级。